Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has announced the recruitment of a second patient for its HG-CT-1 clinical trial, a CAR-T cell therapy aimed at treating relapsed or refractory acute myeloid leukemia in adults. This development signifies progress in their clinical program and highlights the company’s commitment to addressing unmet medical needs in AML treatment.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
YTD Price Performance: -56.23%
Average Trading Volume: 29,289
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £6.39M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.